by Increase in the number of vitiligo patients, expanding awareness pertaining to hypopigmentation disorders, and rise in new product launches by key players are generating substantial business opportunities in the global hypopigmentation disorder treatment market.
In the health condition hypopigmentation, an individual has skin patches of lighter color than the overall skin color. The health conditions such as albinism and vitiligo can be experienced by an individual due to several reasons such as injury, disease, burns, or other traumas.
Get the sample copy of report@ https://qyresearchmedical.com/sample/111962
For treating albinism and vitiligo, several treatment solutions such as laser therapy, topical drugs, microdermabrasion, chemical peels, and phototherapy are used. These treatments are available in aesthetic clinics & dermatology centers and hospitals.
Enterprises from the global hypopigmentation disorder treatment market are expected to observe surge in the product demand from aesthetic clinics & dermatology centers, due to rise in the number of qualified physicians carrying out different cosmetic procedures used in the pigmentation disorders treatments.
Companies in the global hypopigmentation disorder treatment market are increasing investments in the R&D projects in order to advance the quality of products they offer. Moreover, several players are focused on collaboration and acquisition strategies and maintaining their leading positions in the global market for hypopigmentation disorder treatment.
Players in hypopigmentation disorder treatment market are creating newer policies and strategies that focus on recovering from the losses companies encountered due to the COVID-19 pandemic. Key players operating in the global hypopigmentation disorder treatment market are Allergan, SkinCeuticals, Episciences, Inc., Obagi Cosmeceuticals LLC (Obagi Medical), Pierre Fabre, Alvogen, and RXi Pharmaceuticals Corporation.
The hypopigmentation disorder treatment market is expected to gain lucrative opportunities in the North America region. This market growth can be ascribed to many factors such as presence of strong healthcare infrastructure, considerable number of patient pool, and new product approvals in the region.
Hypopigmentation Disorder Treatment Market – Snapshot
The global hypopigmentation disorder treatment market is driven by the rise in prevalence of vitiligo. Growth of the market is attributed to increase in awareness about hypopigmentation disorders and rich product pipeline.
Hypopigmentation is characterized by patches of skin that are lighter than the overall skin tone. The absence of normal amount of melanin (chemical that gives skin its color) caused by disease, injury, burns, or other trauma could lead to hypopigmentation. Hypopigmentation disorders include vitiligo and albinism. Treatments of this disease include topical drugs, laser therapy, chemical peels, microdermabrasion, and others (phototherapy, etc.). Rise in prevalence of acute hypopigmentation disorders such as vitiligo and albinism is anticipated to increase demand for therapeutics, which in turn is expected to drive the global hypopigmentation disorder treatment market. According to the Global Vitiligo Foundation, currently, 70 million people across the world have vitiligo. Moreover, increase in health care expenditure and rise in the number of clinical trials are expected to propel the global hypopigmentation disorder treatment market.
hypopigmentation disorder treatment market
The global hypopigmentation disorder treatment market has been segmented based on treatment, end-user, and region. In terms of treatment, the global market has been classified into topical drugs, laser therapy, chemical peels, microdermabrasion, and others (phototherapy, etc.). The topical drugs segment accounted for major share of the global market in terms of revenue in 2017. The segment is projected to expand at a high CAGR during the forecast period due to increase in the number of patients with hypopigmentation disorders visiting dermatologists and topical drugs being prescribed to these patients. Based on disease indication, the global hypopigmentation disorder treatment market has been categorized into vitiligo, albinism, and others. The vitiligo segment dominated the global market in 2017 due to rise in the number of patients undergoing treatment for vitiligo.
In terms of end-user, the global hypopigmentation disorder treatment market has been divided into hospitals, aesthetic clinics & dermatology centers, and others. The aesthetic clinics & dermatology centers segment dominated the global market in 2017. The trend is likely to continue during the forecast period. Factors driving the segment are increase in the number of trained physicians who can perform cosmetic procedures to treat pigmentation disorders and rise in the number of patients with skin pigmentation.
In terms of region, the global hypopigmentation disorder treatment market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominated the global market in 2017 and is projected to gain market share from 2018 to 2026. The market in North America is driven by increase in incidence of hypopigmentation disorders, new product approvals, strong product pipeline, and rise in health care expenditure. The hypopigmentation disorder treatment market in Asia Pacific is anticipated to expand at a rapid pace during the forecast period. China dominated the market in the region in 2017 due to high population of patients with vitiligo.
Major players operating in the global hypopigmentation disorder treatment market include Allergan, SkinCeuticals, Pierre Fabre, Episciences, Inc., RXi Pharmaceuticals Corporation, Obagi Cosmeceuticals LLC (Obagi Medical), and Alvogen. These companies have adopted the strategy of acquisition and collaboration to strengthen their positions in the global market.
Rising Number of Clinical Trials Paves Way for Innovation in Hypopigmentation Disorder Treatment Market
Drive for improvements and technological advancements in healthcare infrastructure, along with rising number of clinical trials to derive efficient solutions for treatment of hypopigmentation disorders is fueling a wave of innovations in global hypopigmentation disorder treatment market. The growth of global pharmaceutical industry indirectly bolsters the growth in the market as well. Other factors influencing the increase in demand in hypopigmentation disorder treatment market include rising prevalence of Vitiligo and availability of cost effective treatment options. However, substantial cost of treatment and risks and complications associated with aesthetic treatments and products can hamper the growth of global hypopigmentation disorder treatment market in coming years. Risk of side effects of cosmetics and hypopigmentation disorders treatments is also a concerning factor for the patients.
Rising demand for effective and affordable hypopigmentation disorder treatment solutions is expected to provide players in global hypopigmentation disorder treatment market with various opportunities for business development. Players in the market are increasingly focused on developing new topical drugs to meet the rising demand. For example, a brand of A. Menarini Singapore Pvt. Ltd., Dermatix, launched a new acne scare care product, that consists of Vitamin B3 to reduce effects of hypopigmentation disorders. Lower cost and higher effectiveness of topical drugs makes them a lucrative treatment option for patients suffering from hypopigmentation disorders. Increasing popularity of chemical peels among partitioning dermatologists and their patients is also anticipated to increase sales in this particular segment in global hypopigmentation disorder treatment market. Treatments such as microdermabrasion and laser therapy have higher costs and therefore can be afforded by very little consumers. However, increasing adoption of these treatment techniques by professionals and rising number of dermatology centers and aesthetic clinics investing in newer devices are anticipated to draw demand in this segment in global hypopigmentation disorder treatment market. Increasing government initiatives designed to disseminate awareness and information regarding skin pigment disorders including vitiligo and albinism are also expected to drive the global hypopigmentation disorder treatment market in coming years.
The global hypopigmentation disorder treatment market has been segmented as below:
Treatment
- Topical Drugs
- Laser
- Chemical Peels
- Microdermabrasion
- Others (phototherapy, etc.)
Disease Indication
- Vitiligo
- Albinism
- Others
End-user
- Hospitals
- Aesthetic Clinics & Dermatology Centers
- Others
Region
- North America
- U.S.
- Canada
- Europe
- Germany
- U.K.
- Italy
- France
- Spain
- Rest of Europe
- Asia Pacific
- India
- China
- Japan
- Australia & New Zealand
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- GCC Countries
- South Africa
- Israel
- Rest of Middle East & Africa
Purchase Complete Report Now@ https://qyresearchmedical.com/report/checkout/111962/2900
